Grifols, ES0171996087

Grifols stock gains as Biopharma growth supports deleveraging

Published on 11/04/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock enters the final quarter with stronger Biopharma demand and a healthier balance sheet. Full-year guidance remains unchanged.

Growth Meets Lower Financial Leverage

Biopharma demand supported stronger quarterly performance and improved profitability.
Cash generation and refinancing strengthened Grifols' financial flexibility.
Investors will focus next on plasma collection expansion and pipeline milestones.

Grifols, ES0171996087, Illustration mit AI erstellt.

Grifols reported stronger third-quarter results on November 2, 2026, as Biopharma demand lifted revenue and profitability. Yahoo Finance reported on November 3 that the company also improved cash generation and reduced leverage while keeping its full-year guidance unchanged.

According to Yahoo Finance, quarterly revenue reached EUR 2.04 billion, up 8.4 percent at constant currency and above the EUR 1.98 billion consensus estimate. Net profit rose 27.9 percent to EUR 162 million, while adjusted EBITDA increased 9.8 percent at constant currency to EUR 538 million, producing a 26.4 percent margin.

Biopharma Drives The Quarter

Biopharma revenue grew 10.3 percent at constant currency. Immunoglobulin sales increased 11.3 percent, with subcutaneous immunoglobulin advancing 40.3 percent. Alpha-1 and specialty proteins also expanded, although albumin revenue declined 13.2 percent amid regulatory factors and elevated inventory levels in China.

Balance Sheet Progress Continues

Free cash flow before mergers and acquisitions reached EUR 208 million during the quarter. Net leverage declined to 3.98 times from 4.2 times a year earlier, while liquidity rose to EUR 2.14 billion. Grifols also refinanced obligations due in 2027, leaving no significant debt maturities until the fourth quarter of 2028.

Management expects to report topline results from the Phase 3 SPARTA study by the end of the fourth quarter. Investors will also track the expansion of plasma collection in Egypt and whether immunoglobulin demand can offset continued weakness in albumin.

The real-time quote of Grifols stock shows the shares traded at 11.18 euros on Lang & Schwarz at 17:09 CET on Wednesday, November 4, 2026.